Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
A Phase 1 Randomized,Double-Blind and Parallel Controlled Single-dose Clinical Trial of Pharmacokinetics, Safety, Tolerability and Immunogenicity of HLX03 Compared With Humira® From China Source in Chinese Healthy Male Subjects
Sponsor: Shanghai Henlius Biotech
This PHASE1 trial investigates Immune System Disorder and is currently completed. Shanghai Henlius Biotech leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Dec 2019 — Dec 2020 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Dec 2017 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Henlius Biotech
For direct contact, visit the study record on ClinicalTrials.gov .